Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02146768 · ClinicalTrials.gov registry record
Low-dose-contrast Cardiac Computed Tomography
A clinical trial, sponsored by Baylor Research Institute.
- Completed
- Registry status
- 142
- Enrollment target
NCT02146768: Completed study, sponsored by Baylor Research Institute.
NCT02146768 is a clinical trial that has completed, run by Baylor Research Institute. The registered enrollment target is 142 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02146768 has completed, sponsored by Baylor Research Institute.
- COMPLETED
- Registry status
- 142 participants
- Enrollment target
Study Summary
Low-dose-contrast CCTA can effectively and safely assess the aortic valve apparatus, and effectively direct the trans-catheter heart valve (THV) size selection by providing accurate annulus sizing, and provide adequate pre-procedural risk-stratification guidance for TAVR/TAVI.
Primary Outcome
Compare quality and safety of traditional-dose-contrast CCTA versus low-dose-contrast from a renal standpoint, by using serum creatinine and MDRD - eGFR.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 142 participants |
| Start Date | 2014-01 |
What the finished NCT02146768 record still lists
NCT02146768 is an observational study that tracks outcomes without assigning an intervention. The registered 142 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02146768 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02146768 about?
NCT02146768 is a clinical study titled "Low-dose-contrast Cardiac Computed Tomography". Low-dose-contrast CCTA can effectively and safely assess the aortic valve apparatus, and effectively direct the trans-catheter heart valve (THV) size selection by providing accurate annulus sizing, and provide adequate pre-procedural risk-stratification guidance for TAVR/TAVI.
What is the current status of trial NCT02146768?
This trial is currently completed. The enrollment target is 142 participants. The study started on 2014-01.
Who is sponsoring clinical trial NCT02146768?
This trial is sponsored by Baylor Research Institute, which has 180 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03933631 · 142 participants · Phase 3
Pilocarpine Use After Kahook Goniotomy
- NCT04938349 · 142 participants · NA
Dual Task Perturbation Training for OAwMCI
- NCT06117254 · 142 participants · NA
Hearing Aids for Veterans With Functional Hearing Difficulties
- NCT06463665 · 142 participants · Phase 2
Efficacy & Safety of Olvimulogene Nanivacirepvec & Platinum-doublet + Physician's Choice of Immune Checkpoint Inhibitor Compared to Docetaxel in NSCL Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia